2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences
2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaOlder adultsCell lymphomaPopulation-based cohort analysisHigh-quality cancer careAnthracycline-containing regimenGuideline-adherent therapyHigh-volume providersNumber of patientsLook-back periodCytotoxic regimensSystemic therapyImproved survivalClinical outcomesReduced hospitalizationsLymphoma patientsCancer careCohort analysisMedicare beneficiariesComplex surgeryDLBCL casesLymphomaClinical volume
2017
The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment
Viola A, Balsamo L, Neglia JP, Brouwers P, Ma X, Kadan-Lottick NS. The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. Journal Of Pediatric Hematology/Oncology 2017, 39: 174-178. PMID: 28085741, PMCID: PMC5364064, DOI: 10.1097/mph.0000000000000761.Peer-Reviewed Original ResearchConceptsLeukemia survivorsNeurocognitive impairmentAttention-deficit/hyperactivity disorder (ADHD) outcomesPediatric acute lymphoblastic leukemia survivorsPediatric acute lymphoblastic leukemia treatmentAcute lymphoblastic leukemia survivorsAcute lymphoblastic leukemia treatmentPotential late effectsAcute lymphoblastic leukemiaMultivariate logistic regressionExecutive Function Parent FormCross-sectional studyOngoing clinical careBehavior Rating InventoryComprehensive neuropsychological assessmentElevated scoresFirst remissionClinical outcomesLymphoblastic leukemiaLate effectsClinical careRating InventoryLeukemia treatmentCognitive impairmentIndex score
2016
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer 2016, 16: 652. PMID: 27538433, PMCID: PMC4991094, DOI: 10.1186/s12885-016-2710-6.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaObservational cohort studyDisease RegistryCohort studyClinical outcomesPatient-reported health-related qualityProspective observational cohort studyBaseline patient characteristicsHigh-risk MDSHealth-related qualityNon-interventional studyPatient-reported outcomesLower-risk MDSHealth economic outcomesMinimal diagnostic criteriaRoutine clinical settingNatural history studiesBackgroundMyelodysplastic syndromesPersistent cytopeniasOlder patientsPatient characteristicsTreatment patternsAlternate diagnosisCentral reviewMyelodysplastic syndrome